University of Arizona Cancer Center
Tucson, AZ
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Accepting patients
MonumenTAL-3
Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Learn more- Bispecific Antibody
- GPRC5D
- Randomization
- Phase 3
Not yet accepting
Selinexor
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Selinexor, Pomalidomide and Dexamethasone vs Elotuzumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Learn more- SINE
- Randomization
- Phase 3
Accepting patients
DREAMM13
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
Learn more- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 1
Accepting patients
DRAMMATIC
S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more- Monoclonal Antibody
- CD38
- Maintenance
- Phase 3
Accepting patients
EQUATE
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Learn more- Monoclonal Antibody
- CD38
- Phase 3
2 hidden based on your filters. Show All